This trial is evaluating whether STI-1492 will improve 1 primary outcome and 3 secondary outcomes in patients with Multiple Myeloma. Measurement will happen over the course of Baseline through study completion at up to approximately 54 months.
This trial requires 54 total participants across 1 different treatment group
This trial involves a single treatment. STI-1492 is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
"Multiple myeloma is a cancer that typically develops slowly, at a rate of one or fewer new cases a year, within weeks to months. The tumor is typically and almost always secretes the abnormal protein myeloma light chain, which is detectable in the blood. It commonly involves the bone marrow and lymph nodes. It is usually fatal in its early stages, but when treated, long-term survival rates can be achieved. A complete remission is not always obtained, and relapse may occur. The disease can occur in either new cases of multiple myeloma or in cases where the individual has had remissions but has suffered new episodes of disease." - Anonymous Online Contributor
"MM causes enlargement of the spleen and the bone marrow. Other signs include low [back pain](https://www.withpower.com/clinical-trials/back-pain), itching and numbness, fatigue, weight loss, loss of appetite, abdominal pain, diarrhea, constipation, and blurred vision." - Anonymous Online Contributor
"Fewer than 10,000 people per year get American with myeloma. In the United Kingdom, the incidence is comparable, and the risk of getting lymphoproliferative disease is higher than in the United States, accounting for most of the excess mortality. This is more likely to be attributable to the higher incidence of multiple myeloma in the United Kingdom." - Anonymous Online Contributor
"The specific cause of multiple myeloma remains unknown. It is hypothesized that some genetic alterations lead to malignant plasma cell proliferation and, thus, clinical presentation of the disease." - Anonymous Online Contributor
"In this population-based sample of people with newly diagnosed MM, more than half had an active treatment and had some treatment for MM. A large number of patients with newly diagnosed MM underwent multiple active treatments." - Anonymous Online Contributor
"With current treatment, a significant proportion of patients can expect to survive 5 years or more without disease progression. Long-term surveillance or prophylactic treatment should be considered in high-risk patients. Future trials will have to make a more rigorous and consistent definition of progression-free survival, e.g. using the European Commission definition of response. Newer anti-immunoglobulin therapies have now been tested in phase II trials and have shown strong activity in multiple myeloma but more data is being needed to elucidate their role in the treatment of this disease." - Anonymous Online Contributor
"As multiple myelomas progress, symptomatic improvement is needed and patients may not want standard treatment, which might include supportive care and supportive care alone. Physicians should consider multiple myeloma clinical trials." - Anonymous Online Contributor
"The most common side effects from sti-1492 can be categorized into three categories: (1) skin and subcutaneous reactions, (2) GI tract reactions and (3) bone reaction or pain. The most common side effects are a mild decrease of neutrophil and thrombocytosis at the beginning of the administration of the drug, whereas no effect on the neutrophils and platelets were observed at the end of the administration of sti-1492. No haemorrhagic complication was observed in any of the patients. There was no effect on their serum glucose level, and no significant increase on the serum creatinine level was observed at the end of the administration of sti-1492." - Anonymous Online Contributor
"There were few similarities between those patients with and without complications, including a slightly greater prevalence of smoking. There were weak correlations between BMI and biochemical parameters in our study, but this result awaits confirmation in prospective evaluations." - Anonymous Online Contributor
"Results from a recent clinical trial we have demonstrated that Sti-1492, a synthetic small molecule TKI, induces apoptosis in multiple myeloma cells in vitro, suggesting that it may represent a potentially new class of selective agents." - Anonymous Online Contributor
"Survival analysis indicates survival benefit of autologous stem cell [transplant](https://www.withpower.com/clinical-trials/transplant)ation and high-dose thalidomide. With current treatment it is hard to predict what patient or treatment will result in improved survival rates or if improved survival can be expected at all in future treatment strategies for multiple myeloma." - Anonymous Online Contributor
"Recent findings indicate that in our study, Sti-1492 is highly effective in ameloblastoma. This result adds new insight into our knowledge of the anti-oncogenic activity of the TAK-232 analog, and reinforces the concept of Sti-1492 as a potential candidate for the development of a novel anti-cancer drug." - Anonymous Online Contributor